131 related articles for article (PubMed ID: 36738497)
1. Microalga Chlorella sp. extract induced apoptotic cell death of cholangiocarcinoma via AKT/mTOR signaling pathway.
Sawasdee N; Jantakee K; Wathikthinnakon M; Panwong S; Pekkoh J; Duangjan K; Yenchitsomanus PT; Panya A
Biomed Pharmacother; 2023 Apr; 160():114306. PubMed ID: 36738497
[TBL] [Abstract][Full Text] [Related]
2. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma.
Ewald F; Grabinski N; Grottke A; Windhorst S; Nörz D; Carstensen L; Staufer K; Hofmann BT; Diehl F; David K; Schumacher U; Nashan B; Jücker M
Int J Cancer; 2013 Nov; 133(9):2065-76. PubMed ID: 23588885
[TBL] [Abstract][Full Text] [Related]
3. Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy.
Yothaisong S; Dokduang H; Techasen A; Namwat N; Yongvanit P; Bhudhisawasdi V; Puapairoj A; Riggins GJ; Loilome W
Tumour Biol; 2013 Dec; 34(6):3637-48. PubMed ID: 23832540
[TBL] [Abstract][Full Text] [Related]
4. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway.
Shen H; Zhang J; Zhang Y; Feng Q; Wang H; Li G; Jiang W; Li X
Gene; 2019 May; 698():50-60. PubMed ID: 30822475
[TBL] [Abstract][Full Text] [Related]
5. Atractylodin inhibited the migration and induced autophagy in cholangiocarcinoma cells via PI3K/AKT/mTOR and p38MAPK signalling pathways.
Acharya B; Chaijaroenkul W; Na-Bangchang K
J Pharm Pharmacol; 2021 Aug; 73(9):1191-1200. PubMed ID: 33885818
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma.
Chen MH; Chiang KC; Cheng CT; Huang SC; Chen YY; Chen TW; Yeh TS; Jan YY; Wang HM; Weng JJ; Chang PM; Liu CY; Li CP; Chao Y; Chen MH; Huang CY; Yeh CN
Oncotarget; 2014 May; 5(9):2372-89. PubMed ID: 24796583
[TBL] [Abstract][Full Text] [Related]
7. Dual Inhibition of PI3K-AKT-mTOR- and RAF-MEK-ERK-signaling is synergistic in cholangiocarcinoma and reverses acquired resistance to MEK-inhibitors.
Ewald F; Nörz D; Grottke A; Hofmann BT; Nashan B; Jücker M
Invest New Drugs; 2014 Dec; 32(6):1144-54. PubMed ID: 25152244
[TBL] [Abstract][Full Text] [Related]
8. Compound C induces protective autophagy in human cholangiocarcinoma cells via Akt/mTOR-independent pathway.
Zhao X; Luo G; Cheng Y; Yu W; Chen R; Xiao B; Xiang Y; Feng C; Fu W; Duan C; Yao F; Xia X; Tao Q; Wei M; Dai R
J Cell Biochem; 2018 Jul; 119(7):5538-5550. PubMed ID: 29384220
[TBL] [Abstract][Full Text] [Related]
9. Curcumin suppresses proliferation and induces apoptosis in human biliary cancer cells through modulation of multiple cell signaling pathways.
Prakobwong S; Gupta SC; Kim JH; Sung B; Pinlaor P; Hiraku Y; Wongkham S; Sripa B; Pinlaor S; Aggarwal BB
Carcinogenesis; 2011 Sep; 32(9):1372-80. PubMed ID: 21325634
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of FGFR2 enhances chemosensitivity to gemcitabine in cholangiocarcinoma through the AKT/mTOR and EMT signaling pathways.
Jaidee R; Kukongviriyapan V; Senggunprai L; Prawan A; Jusakul A; Laphanuwat P; Kongpetch S
Life Sci; 2022 May; 296():120427. PubMed ID: 35218764
[TBL] [Abstract][Full Text] [Related]
11. GDC-0980 (apitolisib) treatment with gemcitabine and/or cisplatin synergistically reduces cholangiocarcinoma cell growth by suppressing the PI3K/Akt/mTOR pathway.
Jang DK; Lee YG; Chan Chae Y; Lee JK; Paik WH; Lee SH; Kim YT; Ryu JK
Biochem Biophys Res Commun; 2020 Sep; 529(4):1242-1248. PubMed ID: 32819590
[TBL] [Abstract][Full Text] [Related]
12. Triptolide inhibits intrahepatic cholangiocarcinoma growth by suppressing glycolysis via the AKT/mTOR pathway.
Li L; Wang C; Qiu Z; Deng D; Chen X; Wang Q; Meng Y; Zhang B; Zheng G; Hu J
Phytomedicine; 2023 Jan; 109():154575. PubMed ID: 36610163
[TBL] [Abstract][Full Text] [Related]
13. Derrischalcone suppresses cholangiocarcinoma cells through targeting ROS-mediated mitochondrial cell death, Akt/mTOR, and FAK pathways.
Wandee J; Srinontong P; Prawan A; Senggunprai L; Kongpetch S; Yenjai C; Kukongviriyapan V
Naunyn Schmiedebergs Arch Pharmacol; 2021 Sep; 394(9):1929-1940. PubMed ID: 34086099
[TBL] [Abstract][Full Text] [Related]
14. Rosemary extract reduces Akt/mTOR/p70S6K activation and inhibits proliferation and survival of A549 human lung cancer cells.
Moore J; Megaly M; MacNeil AJ; Klentrou P; Tsiani E
Biomed Pharmacother; 2016 Oct; 83():725-732. PubMed ID: 27470574
[TBL] [Abstract][Full Text] [Related]
15. TMEM16A partners with mTOR to influence pathways of cell survival, proliferation, and migration in cholangiocarcinoma.
Kulkarni S; Li Q; Singhi AD; Liu S; Monga SP; Feranchak AP
Am J Physiol Gastrointest Liver Physiol; 2023 Aug; 325(2):G122-G134. PubMed ID: 37219012
[TBL] [Abstract][Full Text] [Related]
16. Extract from Astragalus membranaceus inhibit breast cancer cells proliferation via PI3K/AKT/mTOR signaling pathway.
Zhou R; Chen H; Chen J; Chen X; Wen Y; Xu L
BMC Complement Altern Med; 2018 Mar; 18(1):83. PubMed ID: 29523109
[TBL] [Abstract][Full Text] [Related]
17. Cannabidiol and Cannabigerol Inhibit Cholangiocarcinoma Growth In Vitro via Divergent Cell Death Pathways.
Viereckl MJ; Krutsinger K; Apawu A; Gu J; Cardona B; Barratt D; Han Y
Biomolecules; 2022 Jun; 12(6):. PubMed ID: 35740979
[TBL] [Abstract][Full Text] [Related]
18. Cordycepin reprogramming lipid metabolism to block metastasis and EMT via ERO1A/mTOR/SREBP1 axis in cholangiocarcinoma.
Zhou X; Li Y; Yang C; Chen D; Wang T; Liu T; Yan W; Su Z; Peng B; Ren X
Life Sci; 2023 Aug; 327():121698. PubMed ID: 37080351
[TBL] [Abstract][Full Text] [Related]
19. Survival pathway of cholangiocarcinoma via AKT/mTOR signaling to escape RAF/MEK/ERK pathway inhibition by sorafenib.
Yokoi K; Kobayashi A; Motoyama H; Kitazawa M; Shimizu A; Notake T; Yokoyama T; Matsumura T; Takeoka M; Miyagawa SI
Oncol Rep; 2018 Feb; 39(2):843-850. PubMed ID: 29251327
[TBL] [Abstract][Full Text] [Related]
20. Activation of the Akt/mammalian target of rapamycin pathway in combined hepatocellular carcinoma and cholangiocarcinoma: significant correlation between p-4E-BP1 expression in cholangiocarcinoma component and prognosis.
Okumura Y; Kohashi K; Tanaka Y; Kato M; Maehara Y; Ogawa Y; Oda Y
Virchows Arch; 2020 Jun; 476(6):881-890. PubMed ID: 31927624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
